ENDV (Endonovo Therapeutics) Receivables Turnover: 0.00 (As of Jun. 2025)


What is Endonovo Therapeutics Receivables Turnover?

Endonovo Therapeutics ENDV Receivables Turnover is 0.00 as of Jun. 2025. The stock has 3 warning signs investors should review. Among 843 Biotechnology companies, Endonovo Therapeutics ranks worse than 118623.84% on this metric.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Endonovo Therapeutics's Revenue for the three months ended in Jun. 2025 was $0.00 Mil. Endonovo Therapeutics's average Accounts Receivable for the three months ended in Jun. 2025 was $0.00 Mil.


Endonovo Therapeutics  (OTCPK:ENDV) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Endonovo Therapeutics Receivables Turnover Related Terms


Endonovo Therapeutics Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Receivables Turnover Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.83 73.00 135.00 0.00 0.00

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ENDV vs RGBP, SIGY, CNBX: Receivables Turnover Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Receivables Turnover falls into.



Endonovo Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Endonovo Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Receivables Turnover (A: Dec. 2024 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2024 ) / ((Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count )
=0.01 / ((0 + 0) / 1 )
=0.01 / 0
=N/A

Endonovo Therapeutics's Receivables Turnover for the quarter that ended in Jun. 2025 is calculated as

Receivables Turnover (Q: Jun. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2025 ) / ((Accounts Receivable (Q: Mar. 2025 ) + Accounts Receivable (Q: Jun. 2025 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.00 mean?
Endonovo Therapeutics (ENDV) has a Receivables Turnover of 0.00 as of Jun. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Endonovo Therapeutics and its competitors. According to the industry distribution chart, Endonovo Therapeutics ranks #999999 out of 843 companies in the Biotechnology industry.
Is Endonovo Therapeutics' Receivables Turnover too high?
Endonovo Therapeutics' current Receivables Turnover is 0.00. Based on the distribution chart, Endonovo Therapeutics ranks #999999 out of 843 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' Receivables Turnover compare to RGBP and SIGY?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #999999 out of 843 companies for Receivables Turnover. This places Endonovo Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Endonovo Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Endonovo Therapeutics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Receivables Turnover is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.